Results from the German AIO KRK-0306 study, FIRE-3, show that the addition of cetuximab (Erbitux) to chemotherapy rather than bevacizumab (Avastin) increased overall survival by nearly 4 months in patients with KRAS wild-type metastatic colorectal cancer.
The David A. Karnofsky Memorial Award, ASCO’s highest scientific honor, went this year to Dr. Martine J. Piccart, who is internationally recognized for her unflagging dedication and innovative approaches to the development of drugs and regimens that will truly make a difference in the lives of patients with breast cancer.
Data presented at ASCO from the phase III DECISION trial showed treatment with the TKI sorafenib (Nexavar) delayed disease progression by 5 months in patients with metastatic differentiated thyroid cancer that had progressed on radioactive iodine.
A single-center study analyzed the frequency of breast cancer susceptibility mutations among black women diagnosed with breast cancer. The findings suggest that broader genetic screening may be beneficial for these women. The study also suggests that family history is not the only criteria by which patients at risk for breast cancer can be identified.
In a study presented at ASCO, a team of researchers used microarrays to characterize 130 triple-negative breast cancer patients treated with neoadjuvant chemotherapy to see whether certain subtypes are more likely to respond to the treatment.